AI制药商Turbine获得2500万美元B轮融资-动脉网

Virtual biology company secures $25m for virtual cell models

D-Pharm 等信源发布 2026-03-04 12:53



可切换为仅中文







Turbine announced a $25 million

Turbine 宣布了 2500 万美元的

Series B financing

B轮融资

, an expansion of its virtual cell platform across industries and a new immunology-focused partnership with a top 10 pharma company. The Series B round is led by Interactive Venture Partners, with participation from Beiersdorf AG and existing investors, including MSD Global Health Innovation, Accel and Mercia..

，将其虚拟细胞平台扩展到各个行业，并与一家排名前十的制药公司建立了新的免疫学合作。B轮融资由Interactive Venture Partners领投，Beiersdorf AG和现有投资者参与，包括MSD全球健康创新基金、Accel和Mercia。

“Central and Eastern Europe has produced exceptional innovation, and Turbine stands out as one of the region’s most compelling virtual biology platforms. Our team assessed the opportunity from both a technology and life sciences perspective, and we believe the ambitious team’s unique capability to virtualize biological experiments with AI positions them to be among the global leaders embedding such technology into biopharma R&D,” said Laszlo Czirjak, Managing Partner at Interactive VP, a fund backed by the family office of Thomas Peterffy, Founder and Chairman of Interactive Brokers Group, Inc..

“中欧和东欧在创新方面表现出色，Turbine 作为该地区最引人注目的虚拟生物学平台之一脱颖而出。我们的团队从技术和生命科学的角度评估了这一机会，我们认为这支雄心勃勃的团队利用人工智能虚拟化生物实验的独特能力，使他们有望成为将此类技术应用于生物制药研发的全球领导者之一。” Interactive VP 基金的管理合伙人 Laszlo Czirjak 表示。该基金由盈透证券集团创始人兼董事长 Thomas Peterffy 的家族办公室支持。

With the new funding, Turbine will expand its platform to virtualize new assays across discovery and translational medicine. Turbine’s lab-in-the-loop will generate additional proprietary perturbation datasets, allowing the company to fine-tune its foundational virtual cell model to novel assay and tissue types.

通过这笔新的资金，Turbine 将扩展其平台，以在发现和转化医学领域虚拟化新的检测方法。Turbine 的闭环实验室将生成额外的专有扰动数据集，使公司能够将其基础虚拟细胞模型微调至新的检测方法和组织类型。

These virtual assays are deployed through the company’s Virtual Lab, a no-code platform that integrates with pharma workflows and systems..

这些虚拟检测通过该公司的虚拟实验室部署，这是一个与制药工作流程和系统集成的无代码平台。

“At Beiersdorf Venture Capital we see clear potential in AI-driven technologies such as virtual cell models that help researchers assess how active ingredients interact with skin biology, skin conditions, and safety. Our investment in Turbine reflects our interest in deep‑tech approaches that could shape the future of skin research.” – Ascan Voswinckel (Head of Beiersdorf Venture Capital).

“在拜尔斯道夫风险投资公司，我们看到人工智能驱动技术的明显潜力，例如帮助研究人员评估活性成分如何与皮肤生物学、皮肤状况和安全性相互作用的虚拟细胞模型。我们对Turbine的投资反映了我们对可能塑造皮肤研究未来的深度技术方法的兴趣。”——阿斯坎·沃斯温克尔（拜尔斯道夫风险投资公司负责人）。

With the new momentum from the investment round, Turbine is expanding its oncology-focused offering in biopharma to include immunology through a newly announced collaboration with a top 10 pharma company. Per the agreement, Turbine’s virtual assays will be trained to model immune cell behavior using proprietary datasets provided by the partner.

借助这轮融资的新动力，Turbine 正在扩展其在生物制药领域专注于肿瘤学的产品，通过与一家排名前十的制药公司新宣布的合作，将免疫学纳入其中。根据协议，Turbine 的虚拟分析技术将利用合作伙伴提供的专有数据集，训练建模免疫细胞行为。

The companies aim to provide deep mechanistic insights into immune pathways to inform the identification and prioritization of novel therapeutic combinations. The collaboration will enable scientists to run virtual experiments at a massive scale and interpret in silico results in the Virtual Lab so that only high conviction hypotheses proceed to wet lab validation..

这些公司旨在提供对免疫通路的深入机制洞察，以帮助确定和优先考虑新的治疗组合。该合作将使科学家能够大规模运行虚拟实验，并在虚拟实验室中解读计算机模拟结果，从而确保只有高可信度的假设进入湿实验室验证。

“Combination therapies have been proven to offer patient benefit. However, given the complexity of immunological diseases and the sheer number of potential combinations, virtualization is the only way scientists can rationally explore and identify the right drug combinations, as well as which patient cohorts may benefit from them.” said Szabolcs Nagy, Co-Founder & CEO at Turbine.

“组合疗法已被证明可为患者带来益处。然而，鉴于免疫学疾病的复杂性以及潜在组合的数量繁多，虚拟化是科学家合理探索和识别正确药物组合以及可能受益的患者群体的唯一途径。”Turbine联合创始人兼首席执行官Szabolcs Nagy表示。

“We are excited to expand into immunology, as a new therapeutic area, to build an active learning loop where simulations inform the right wet lab experiments, which in turn generate data that improves the next round of predictions to ultimately identify a number of potentially successful immunology drug combinations.”.

“我们很高兴将免疫学作为一个新的治疗领域进行扩展，建立一个积极的学习循环，其中模拟结果指导正确的湿实验室实验，从而生成数据以改进下一轮预测，最终确定一些可能成功的免疫学药物组合。”

https://www.bionity.com/en/news/1188205/virtual-biology-company-secures-25m-for-virtual-cell-models.html

https://www.bionity.com/en/news/1188205/虚拟生物公司获得2500万美元用于虚拟细胞模型.html

Start-up aims to open the door to an entirely new approach to immunotherapy

初创公司旨在开启一种全新的免疫疗法方法之门

Pathios Therapeutics raises $25M in first close of Series B financing to advance first-in-class immunotherapy approach into clinic

Pathios Therapeutics 在B轮融资的首次关闭中筹集了2500万美元，以推进其首创的免疫疗法进入临床。

Read news

读新闻